News | September 15, 2014

Patient-Reported Data Indicates Radiotherapy Does Not Increase Risk of Lymphedema in Node-Negative Breast Cancer Patients

September 15, 2014 — A secondary analysis of the National Surgical Adjuvant Breast and Bowel Project B-32 trial (Krag 2010) indicates that radiation therapy does not increase the incidence of lymphedema in patients with node-negative breast cancer, according to research presented this week at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO).

The original NSABP B-32 study was a randomized trial of sentinel node biopsy (SNB) versus SNB + axillary lymph node dissection (ALND) in 5,611 women with clinically node-negative breast cancer. The study was initiated to determine if SNB was as effective as ALND with fewer side effects.

Although designed to assess the impact of type of axillary surgery specifically on lymphedema risk, the NSABP B-32 trial also provided the opportunity to evaluate the impact of radiation therapy on lymphedema risk. Lymphedema, swelling of the arm commonly caused by the removal of or damage to lymph nodes, is a significant concern for women undergoing breast cancer treatment.

Measures of lymphedema were collected at baseline prior to therapy and every six months during the three-year follow-up period. Lymphedema was assessed both by standardized arm measurements by clinicians (objective lymphedema) and via questionnaires completed by patients (subjective lymphedema).

Objective lymphedema (clinician measured) was defined as relative arm volume difference (RAVD) >10 percent, and was determined by a water displacement method. Subjective lymphedema was defined as patient-reported ipsilateral (occurring in the same arm) swelling that was “somewhat,” “quite” or “very” bothersome. Repeated measures analyses, chi-square and Fisher’s exact tests were used to evaluate the association between measures of lymphedema and radiation therapy. Kappa coefficient was used to assess agreement between objective and subjective lymphedema measures at individual time points.

Among 3,916 women in the trial with lymphedema assessments, including 1,936 randomly assigned to SNB+ALND and 1,980 randomly assigned to SNB, 82.2 percent (3,220) received therapy and 17.2 percent (674) did not. The status was unknown for 0.6 percent (22) of the patients. The original study results showed that SNB+ALND were associated with significantly greater risk of lymphedema versus SNB alone.

Upon secondary analysis, researchers found no greater risk of lymphedema among women receiving radiotherapy versus among women who did not. There was no significant difference in standardized arm measurements and no significant difference in patient reports of bothersome arm swelling during three years of follow-up, suggesting that radiation does not contribute to lymphedema risk beyond surgery over time. Interestingly, although receipt of radiation did not impact either, there was a lack of agreement between patient reports of bothersome swelling (subjective lymphedema) and clinician measurements of arm swelling (objective lymphedema) throughout the three years of follow-up.

At 36 months follow-up of the SNB+ALND group that had received therapy, 12.4 percent (147/1,183) had RAVD >10 percent (objective lymphedema), and 7.4 percent (16/216) reported bothersome swelling (subjective lymphedema). Within the SNB+ALND group that did not receive radiation, 16.7 percent (36/216) had RAVD >10 percent and 8.8 percent (5/57) of the group reported bothersome swelling.

Within the SNB-only group, 7.4 percent (90/1,218) of radiotherapy recipients had RAVD >10 percent (objective lymphedema) at 36 months of follow-up, with only 3.2 percent (8/250) of those patients reporting bothersome arm swelling. For the SNB-only patients who did not undergo therapy, 4.5 percent (10/220) had RAVD >10 percent, whereas 4.8 percent (3/63) reported bothersome swelling.

“These results provide much needed reassurance to breast cancer patients regarding the impact of radiation therapy on lymphedema risk,” said lead study author Susan McCloskey, M.D., MSHS, assistant professor of radiation oncology at The David Geffen School of Medicine at University of California, Los Angeles. “The study findings argue convincingly that radiation therapy to the Level 1 axilla, considered unavoidable ‘collateral damage’ when radiating the whole breast, does not contribute to lymphedema risk beyond surgery. Several recent analyses have suggested that mastectomy rates are on the rise in the United States, and some have suggested that a desire to avoid radiation and its associated toxicities is a contributing factor. This analysis suggests that lymphedema concerns should not be an impediment to women choosing breast conservation and radiation therapy.”

For more information: www.astro.org

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Mobile App Data Collection Shows Promise for Population Health Surveys
News | Population Health | January 10, 2019
Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...